Frontline

SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.» Mehr auf globenewswire.com

CHICAGO--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) today unveiled the V200, a body camera designed specifically to help protect frontline workers in stores, hospitals, hotels, schools and stadiums. Workers in these settings regularly face safety concerns – from unwelcome behavior to theft and medical emergencies – and the V200, with its GoLive Audio safety feature, offers a direct connection to help. The V200 body camera is a discreet, lightweight addition to a worker's uniform. The recor.» Mehr auf businesswire.com

Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten.» Mehr auf seekingalpha.com